• Consensus Rating: Hold
  • Consensus Price Target: $5.00
  • Forecasted Upside: 110.08%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.38
+0 (0.00%)

This chart shows the closing price for BCDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioCardia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCDA

Analyst Price Target is $5.00
▲ +110.08% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for BioCardia in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 110.08% upside from the last price of $2.38.

This chart shows the closing price for BCDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in BioCardia. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/6/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/5/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2022Alliance Global PartnersLower Target$11.50 ➝ $6.00Low
11/11/2022Dawson JamesDowngradeBuy ➝ NeutralLow
5/26/2022Maxim GroupLower Target$4.00Low
2/3/2022Brookline Capital ManagementReiterated RatingBuyHigh
12/20/2021HC WainwrightInitiated CoverageBuy$9.00Low
4/22/2021Dawson JamesReiterated RatingBuy ➝ NeutralMedium
4/16/2021Dawson JamesDowngradeBuy ➝ NeutralHigh
9/21/2020Alliance Global PartnersInitiated CoverageBuy$11.50High
8/14/2020Maxim GroupInitiated CoverageBuy$7.00Medium
5/1/2020Maxim GroupInitiated CoverageBuy$9.00Low
4/1/2020Maxim GroupReiterated RatingBuy$9.00High
11/26/2019Brookline Capital ManagementReiterated RatingBuyLow
11/26/2019Brookline Capital ManagementInitiated CoverageBuy$22.00Low
10/10/2019Maxim GroupInitiated CoverageBuy$9.00 ➝ $9.00High
9/17/2019Dawson JamesInitiated CoverageBuy$24.00Low
9/17/2019Dawson JamesReiterated RatingBuyMedium
(Data available from 2/6/2018 forward)

News Sentiment Rating

1.34 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
8/10/2022
  • 2 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
10/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/7/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2023

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
BioCardia logo
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brands. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.
Read More

Today's Range

Now: $2.38
Low: $2.35
High: $2.43

50 Day Range

MA: $2.06
Low: $1.61
High: $2.54

52 Week Range

Now: $2.38
Low: $1.10
High: $2.85

Volume

50,500 shs

Average Volume

41,448 shs

Market Capitalization

$47.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of BioCardia?

The following equities research analysts have issued stock ratings on BioCardia in the last year: Alliance Global Partners, Dawson James, and Maxim Group.
View the latest analyst ratings for BCDA.

What is the current price target for BioCardia?

2 Wall Street analysts have set twelve-month price targets for BioCardia in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 110.1%. Alliance Global Partners has the highest price target set, predicting BCDA will reach $6.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $4.00 for BioCardia in the next year.
View the latest price targets for BCDA.

What is the current consensus analyst rating for BioCardia?

BioCardia currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BCDA, but not buy more shares or sell existing shares.
View the latest ratings for BCDA.

What other companies compete with BioCardia?

How do I contact BioCardia's investor relations team?

BioCardia's physical mailing address is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. The company's listed phone number is (650) 226-0120 and its investor relations email address is [email protected] The official website for BioCardia is www.biocardia.com. Learn More about contacing BioCardia investor relations.